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ABSTRACT
Background and objective: Survivin is an inhibitor of apoptosis. Its role in guiding 
the treatment of neoplasms, making diagnosis and predicting prognosis has been 
reported. However, there is little information on the implications and uses of survivin 
in predicting pituitary adenoma (PA) invasiveness. Existing information is unclear 
and controversial. We thus conducted this meta-analysis to explore whether the 
surviving expression levels in invasive PAs (IPA) and regular PAs are different or not. 
We considered both non-secreting and secreting tumors together.
Methods: A global search strategy was systematically applied among five 
databases including Cochrane Library, Embase, PubMed, Web of Science, and 
Chinese National Knowledge Infrastructure (CNKI) up to June 18th, 2017. With a 
specially designed form including PAs’ invasive features, etc., data was collected. 
The included studies should present the data representing the surviving levels 
in IPA groups and regular PA groups, respectively. Differences were expressed 
as standard mean differences (SMDs) or odds ratios (ORs) with 95% confidence 
interval (CI). To estimate the heterogeneities, I2 test, Cochran’s Q-test and Galbr 
figure were all conducted. A sensitivity-analysis and potential-publication bias 
were also performed.
Results: In the present meta-analysis, 9 studies containing 489 patients 
were included. Seven studies with dichotomous-data showed that survivin over-
expression in PA tissue was closely associated with a high invasive tendency (OR 
6.226, 95% CI 3.970, 9.765; P<0.001), but 2 continuous-data studies revealed 
that there was no significant association (SMD -5.043, 95% CI-10.965, 0.878; 
p=0.095). A sensitivity-analysis suggested a statistically stable result. We did not 
find publication bias.
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Conclusion: We suggest that survivin overexpression is potentially associated 
with PA invasiveness. More research based on medical big data is needed to confirm 
this finding.
INTRODUCTION
Pituitary adenomas (PAs) represent 10% to 25% 
of all intracranial neoplasms. PAs are generally divided 
into two categories based on their ability to invade the 
surrounding tissues; approximately 40% are invasive PAs 
(IPA) and most are being benign PAs [1]. Generally, IPAs 
are considered adenomas with proven growth to adjacent 
structures, like sphenoid sinus, bone and cavernous 
sinuses. The invasiveness can be observed through pre-
surgical MRI, during surgery, or with histopathological 
analysis and demonstration of tumor spread to the bone, 
dura or nasal mucosa. The most common used method 
to identify invasion is sellar MRI and the Knosp grading 
system is also widely used [2]. However, the cellular 
morphological differences between these two types 
of PAs are mostly not significant, and it is difficult 
for neurosurgeons to distinguish between them using 
traditional pathological tests. Thus, precise diagnosis or 
treatment of IPA remains a challenge. The resection rate 
of IPA is low and the surgical risk, the mortality rate and 
the recurrence rate are high [3]. Therefore, it is necessary 
to explore new avenues such as available biomarkers.
Located on 17q25.3, survivin is considered to be an 
inhibitor of apoptosis [4]. Survivin level increased in many 
human tumors including lung cancer [5], breast cancer [6] 
and gliomas [7]. Some studies also confirmed that survivin 
is closely associated with PA invasiveness and tumorigenesis 
by blocking apoptosis via an effect on caspase-9, which is 
activated through extrinsic and intrinsic pathways [8, 9]. 
Survivin is thus considered to be a potential bio-marker for 
prognosis and a potential bio-target for treatment.
The values of survivin in PA invasiveness, however, 
is still unknown, and there have been conflicting reports [8, 
9]. A few studies showed that a high survivin expression is 
associated with PA invasiveness [10], while Waligorska-
Stachura et al. did not find any significant changes in 
the survivin level and in its splice variant transcripts in 
invasive and non-invasive PAs [8]. Many confounding 
factors may affect the study outcomes, such as follow-up, 
selected population, and study methods. Considering that a 
meta-analysis can solve between-study heterogeneities, we 
extracted all data from previous studies and systematically 
evaluated the essential implications of survivin in PA 
invasive features.
RESULTS
Search results and study characteristics
According to PRISMA statement, a study selection 
flowchart was reported in Figure 1. A total of 151 studies 
were identified in search: 26 in Pubmed, 31 in Embase, 
0 in Cochrane Library, 25 in Web of Science, and 33 in 
CNKI (Table 1). According to their title and abstract, 
86 articles were excluded for the following reasons: 
21 for no correlation with PA’s invasiveness; 35 for no 
correlation with survivin; and 30 for in vitro and in vivo 
studies. The remaining 65 articles underwent further 
evaluation and screening; among these, 50 articles were 
excluded because they were reviews, or had insufficient 
data or no survivin data. Finally, a total of 9 articles met 
the inclusion criteria, eight of which were conducted in 
China and one in Poland. Table 2 was used to access 
the literature quality. Excluded studies and the rational 
for exclusion were listed in Table 3. The characteristics 
and methodological quality assessment results of the 
literatures included in this meta-analysis are shown in 
Table 4.
A total of 489 patients were included and 266 cases 
were of the invasive type. The percentage of positive 
survivin expression varied from 37.9% to 69.7%. Patients 
with positive survivin were further investigated using 
IHC (8 studies) more often than RT-PCR (1 study). If the 
nucleus or cytoplasm was stained, survivin expression was 
considered to be positive. Different studies use different 
cutoff values to distinguish between low and high survivin 
expression. The detailed standards to evaluate the intensity 
of survivin staining are shown in Table 5.
Meta-analysis of survivin and PA invasiveness
We divided PAs into the invasive and non-invasive 
types to merge the data. Data about PA invasive features 
were available in 7 studies with dichotomous-data and 2 
studies with continuous-data (Table 4). In Galbraith plots 
for dichotomous-data studies (Figure 2A), all points fell 
within the appointed area, which indicates that there were 
no statistical heterogeneities across all the studies (Q = 
3.44, d.f. = 6, I2=0.0%). As shown in Figure 3A, using a 
random-effect model, pooled OR indicates correlations 
between survivin expressions and invasiveness (OR 
6.226, 95% CI 3.970, 9.765; P<0.001). These suggested 
that high survivin expression in postoperative PA tissues 
can predict a high invasive tendency. Conversely, in 
Galbraith plots for the continuous-data studies (Figure 
2B), there are points that fall outside the area, suggesting 
relatively high heterogeneities (Q = 33.72, d.f. = 1, I2 = 
97.0%). As shown in Figure 3B, also using a random-
effect model, the SMDs of the 2 studies didn’t suggest 
that survivin expression level was associated with the PA 
invasive tendency (SMD -5.043, 95% CI -10.965, 0.878; 
P = 0.095). All the meta-analysis results were shown in 
Table 6.
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Sensitivity analysis and publication bias
Sensitivity-analyses were conducted to calculate 
the influences of each individual study on the integrated 
ORs or SMDs. The results of the analysis suggested 
that no individual studies significantly affected the 
pooled OR of survivin and the invasiveness, indicating 
a statistically robust result (Figure 4). Because there 
were only two included studies with continuous data, a 
sensitivity analysis was not undertaken. Using Begg’s 
and Egger’s tests, no publication biases were detected 
among the 7 studies with dichotomous data (P=0.098, 
95% CI-0.947, 8.118). In addition, a funnel plot 
revealed that the overall distribution was symmetric 
(Figure 5), indicating that there was no significant 
publication bias.
Figure 1: Literature search and selection of articles.
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Verification results
The expression levels of survivin in all invasive PA 
tissues and non-invasive PA tissues were shown in Table 
7. A significant positive correlation was observed between 
survivin expression and the PA’s histopathological 
invasiveness. The invasive PA tissues had much higher 
survivin expression than non-invasive PA tissues (P < 
0.01).
DISCUSSION
The involvements of survivin in tumorigenesis have 
been documented, mainly focusing on apoptosis inhibition 
and cell proliferation control. In recent years, it has been 
found that survivin gene knockdown could decrease the 
malignancies of gliomas [11]. Because of its vital roles 
in tumor cells’ biology, survivin is thus considered to be 
a potential bio-marker for prognosis and a potential bio-
target for treatment. But it’s still not clear enough whether 
survivin also plays important roles in PA invasiveness. To 
date, the impact of survivin on IPA is controversial.
We explored the survivin expressions in 9 
studies and its associations with PA’s invasiveness 
in 489 patients. We conducted quality assessments 
of the included literatures via browsing and scoring 
every article according to the methodological quality 
assessment scale (Table 2). Overall, the scores of the 
nine studies in terms of design, method, generalizability 
and results analysis remains fine, suggesting a relatively 
superior quality. The analysis for the 7 dichotomous-
data studies indicated that survivin over-expression was 
closely correlated with the invasive tendency (OR 6.226, 
95% CI 3.970, 9.765; P<0.001), but the analysis for the 
2 continuous-data studies did not reveal any significant 
associations (SMD -5.043, 95% CI-10.965, 0.878; P = 
0.095). However, the latter 2 studies only make up a 
small part, therefore we believe that the present analysis 
still indicated a relatively strong association between 
survivin overexpression and IPA. Because included data 
are not big enough, on this occasion, more evidence-
based studies are necessary to further support this 
conclusion. The results of the present meta-analysis are 
consistent with the findings of our own study. In this 
study, we obtained tissue samples of 36 invasive PAs and 
31 non-invasive PAs. The tumor samples were diagnosed 
by two pathologists who were blinded to the patient data. 
We adopted immunohistochemical methods to measure 
the expression of survivin in PA tissues. The results 
showed that the expression of survivin was significantly 
lower in non-invasive PA tissues than in invasive tissues 
(p < 0.05, Table 7). Our results further confirmed this 
association.
Galbraith plots, I2 tests and Cochran’s Q-tests were 
all conducted to estimate the heterogeneities among the 
included literatures. A P value > 0.05 and/or I2 < 50% 
indicate homogeneity. The fixed versus random effects 
model should be based on sampling population and 
not purely on heterogeneity considerations. It seems 
likely that there are considerable phenotypic variations 
between populations in the different studies, so we use 
the DerSimonian and Laird random-effects model no 
matter the I2 was higher than 50% or lower than 50%. 
As for limitations, first, most included studies were done 
Table 1: Searching strategies and results for different databases
Database Database URL Search strategy Results
Pubmed https://www.ncbi.nlm.nih.gov/
pubmed/
“pituitary neoplasms”[MeSH Terms] OR (“pituitary”[All 
Fields] AND “neoplasms”[All Fields]) OR “pituitary 
neoplasms”[All Fields] OR (“pituitary”[All Fields] AND 
“adenoma”[All Fields]) OR “pituitary adenoma”[All Fields]) 
AND survivin[All Fields]
26
Embase https://www.embase.com/ ’pituitary’:ab,ti AND ’survivin’:ab,ti 31
Cochrane 
Library
http://www.cochranelibrary.com/ survivin AND pituitary 0
Web of 
Science
http://apps.webofknowledge.com/ TOPIC: (survivin AND pituitary)
Timespan: All years. Indexes: SCI-EXPANDED, SSCI, 
A&HCI, CPCI-S, CPCI-SSH, BKCI-S, BKCI-SSH, ESCI, 
CCR-EXPANDED, IC.
25
CNKI http://www.cnki.net/ 33
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Table 2: Scale for methodological quality assessment
Criteria Score
1. Representativeness of cases
  RA diagnosed according to acknowledged criteria. 2
  Mentioned the diagnosed criteria but not 
specifically described.
1
  Not Mentioned. 0
2. Source of controls
  Population or community based 3
  Hospital-based RA-free controls 2
  Healthy volunteers without total description 1
  RA-free controls with related diseases 0.5
  Not described 0
3. Sample size
  >300 2
  200-300 1
  <200 0
4. Quality control of genotyping methods
  Repetition of partial/total tested samples with a 
different method
2
  Repetition of partial/total tested samples with the 
same method
1
  Not described 0
5. Hardy-Weinberg equilibrium (HWE)
  Hardy-Weinberg equilibrium in control subjects 1
  Hardy-Weinberg disequilibrium in control 
subjects
0
Table 3: Excluded studies and the rational for exclusion
Excluded 
studies
Rational for exclusions
Wasko et al. 
(2005)
This study only explored the survivin 
expression in different types of PAs
Zhang et al. 
(2008)
Not the most complete and the most recent 
article by these authors.
Jankowska et al. 
(2008)
Related data could not be abstracted from 
the results.
Wasko et al. 
(2009)
Comparison of survivin expressed between 
pituitary tumors and normal pituitary.
Formosa et al. 
(2012)
Comparison of survivin expressed between 
pituitary tumors and normal pituitary.
Waligórska-
Stachura et al. 
(2015)
This study only explored the survivin and 
its splice variants ΔEx3 and 2βin different 
types of PA and non-cancerous pituitary 
tissues.
Dellal et al. 
(2015)
This study investigated serum survivin 
levels in patients with prolactinoma and 
demonstrate its value in diagnosis of the 
disease.
Stache et al. 
(2016)
This study investigated the underlying 
mechanisms responsible for high tumor 
recurrence rates of adamantinomatous 
craniopharyngioma, not related to PA.
Waligórska-
Stachura et al. 
(2017)
This study investigated survivin and its 
splice variants DEx3 and 2B expressions in 
PAs and normal pituitary glands, not related 
to PA invasiveness.
Table 4: Characteristics and quality scores of the nine included studies
Year Study ID Ethnicity Number Mean age 
(year)
Male Non-
invasive
Invasive Method Survivin expression 
location
Positive 
(%)
Data type Quality
2005 Shi QH et al. Asian 71 42.5 33 32 39 IHC-SP Nucleus or cytoplasm 43.66 Dichotomous 7
2006 Zhang ZQ 
et al.
Asian 48 35.8 26 21 27 IHC-SP and 
TUNEL
Nucleus or cytoplasm 66.67 Dichotomous 7
2008 Zhou J. et al. Asian 49 43.0(M) 
38.9(F)
23 20 29 IHC-SP Not clear 53.06 Dichotomous 6
2008 Wang CL 
et al.
Asian 82 42 38 31 51 IHC-
MaxVisonTM
Nucleus or cytoplasm 67.07 Dichotomous 8
2008 He XL. et al. Asian 43 47.5 21 28 15 IHC-SP Nucleus or cytoplasm 37.21 Dichotomous 6
2008 Jankowska A 
et al.
Polonais 22 Not clear Not clear 7 15 Quantitative 
RT-PCR
NA NA Continuous 9
2009 Xiang W 
et al.
Asian 50 39 34 20 30 IHC-SP Cytoplasm NA Continuous 6
2009 Zhang YC 
et al.
Asian 66 68.1±2.5(M) 
65.3±4.3(F)
36 27 39 IHC-SP Not clear 69.70 Dichotomous 8
2010 Zhang YX 
et al.
Asian 58 42.6 30 37 21 IHC-SP Nucleus or cytoplasm 37.93 Dichotomous 7
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in Asian populations, which may have led to selection 
bias. Second, the criteria or methods adopted to measure 
survivin expressions weren’t consistent. Third, to a large 
extent, IHC results depend largely on methodological 
factors such as primary and secondary antibody titer. It 
was difficult to perform subgroup-analyses involving 
different antibodies to evaluate possible method biases 
regarding the final incorporated results. Moreover, some 
studies did not present complete data, though this might 
not have affected the bias.
Publication-bias is another concern in meta-analyses 
[12]. Most articles tend to report positive outcomes, while 
the articles with negative findings are usually rejected. In 
our study, neither Begger’s and Egger’s P value tests nor 
funnel-plots suggested publication-bias. However, since 
the languages used in the included articles in this meta-
analysis was mainly Chinese and English, there may exist 
potential publication-bias.
CONCLUSION
This meta-analysis indicates that survivin is closely 
associated with high invasive tendency of PAs and it may 
be an important prognostic factor. In addition, survivin 
Table 5: Detailed standards to evaluate the intensity of survivin staining in the included studies
Year Study ID Standards to evaluate the intensity of Survivin staining
2005 Shi QH et al. -, no expression or positive cells was 0%; +, light yellow or ≤10%; ++, brown 
yellow or 11%~50%; +++, brown or 51%~75%; ++++, dark brown or >75%
2006 Zhang ZQ et al. +, positive cells <10%, or the staining degree was light yellow; +++, positive 
cells >60% and most positive cells presented as yellow or brong yellow; ++, 
between the above
2008 Zhou J et al. -, no expression; +, <25%; ++, 25%~50%; +++, >50%
2008 Wang CL et al. -, no expression; +, positive cells <25%; ++, 25%~50%; +++, >50%
2008 He XL et al. -, positive cells <5%; +, >5%
2008 Jankowska A et al. NA
2009 Xiang W et al. Score:0, positive cells <5%; 1, 5%~24%; 2, 25%~49%;3, 50%~74%; 4, ≥75%
2009 Zhang YC et al. -, no expression or positive cells was 0%; +, light yellow or ≤10%; ++, brown 
yellow or 11%~50%; +++, brown/dark brown or >50%
2010 Zhang YX et al. Score A (positive cells):0, <5%; 1, 5%~24%; 2, 25%~49%; 3, 50%~74%; 4, 
≥75%Score B (staining degree of positive cells):0, no staining; 1, light yellow; 2, 
brown yellow; 3, dark brownA*B:Negative, ≤1; Positive, >1
Figure 2: Galbraith figure of included studies focusing on the correlation between survivin and IPA. (A) Seven studies 
with dichotomous data, and (B) Two studies with continuous data. If the circles are all distributed within the region bounded by the upper 
line and the lower line, this suggests that here is homogeneity. The farther away from the region, the more heterogeneity is present.
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detection might facilitate new insights into cancer grades’ 
prediction and early treatment-regimens of patients 
undergoing operational resection. However, not all the 
studies have a perfectly desirable scientific quality and 
there actually exist inconsistent results between the 
dichotomous studies and continuous studies, so to obtain 
a more accurate conclusion, more data obtained using 
medical big data are necessary to support this correlation.
Table 6: The results of the meta-analysis for association between survivin and pituitary adenoma’s invasiveness
Data type Study or 
subgroup
Publishing 
year
Non-invasive groups Invasive groups % Weight OR 95% CI
Negative Positive Total Negative Positive Total
Shi QH et al. 2005 25 7 32 15 24 39 18.10 5.714 [1.984, 16.455]
Zhang ZQ et al. 2006 11 10 21 5 22 27 12.08 4.84 [1.326, 17.666]
Zhou J. et al. 2008 15 5 20 8 21 29 12.00 7.875 [2.148, 28.868]
Wang CL et al. 2008 17 14 31 10 41 51 20.70 4.979 [1.852, 13.386]
Dichotomous He XL. et al. 2008 23 5 28 4 11 15 9.02 12.65 [2.827, 56.597]
Jankowska A et al. 2009 16 11 27 4 35 39 12.20 12.727 [3.510, 46.152]
Zhang YX et al. 2010 27 10 37 9 12 21 15.90 3.6 [1.165, 11.127]
Integrated/pooled 134 62 196 55 166 221 100.00 6.226 [3.970, 9.765]
Heterogeneity chi-squared = 3.44 (d.f. = 6) p = 0.752
I-squared (variation in OR attributable to heterogeneity) 
= 0.0%
Estimate of between-study variance Tau-squared 
= 0.0000
Test of OR=1 : z= 7.97 p = 0.000
Study or 
subgroup
Publishing 
year
Non-invasive groups Invasive groups % Weight SMD 95% CI
n1 mean1 sd1 n2 mean2 sd2
Jankowska et al. 2008 7 5.5 0.225 15 6 0.25 50.62 -2.06 [-3.161, -0.959]
Continuous Xiang et al. 2009 20 3.09 1.03 30 10.28 0.78 49.38 -8.102 [-9.819, -6.385]
Integrated/pooled 27 - - 45 - - 100 -5.043 [-10.965, 0.878]
Heterogeneity chi-squared = 33.72 (d.f. = 1) p = 0.000
I-squared (variation in SMD attributable to 
heterogeneity) = 97.0%
Estimate of between-study variance Tau-squared 
= 17.7150
Test of SMD=0 : z= 1.67 p = 0.095
Figure 3: Individual and pooled effects of survivin and IPA. (A) Using a random-effect model, seven studies with dichotomous 
data (OR 6.260, 95% CI 4.011, 9.770; P<0.001) showed an association between survivin and invasiveness. (B) Using a random-effect model, 
three studies with continuous data (SMD -5.043, 95% CI -10.965, 0.878; P = 0.095) also suggested that the association was statistically 
significant.
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Figure 4: Sensitivity analyses of the seven dichotomous studies. Results were computed by omitting each study in turn. Meta-
analysis random-effect estimates (exponential form) were used. The two ends of the dotted lines represent the 95% CI.
Figure 5: Funnel plot designed to visualize a potential publication bias.
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MATERIALS AND METHODS
Search strategy
A global search strategy was systematically 
applied among five databases including Cochrane 
Library, Embase, PubMed, Web of Science, and Chinese 
National Knowledge Infrastructure (CNKI) up to June 
18th, 2017. No language restriction was set. Detailed 
searching strategies were in Table 1. For PubMed, 
we adopted “(“pituitary neoplasms”[MeSH Terms] 
OR (“pituitary”[All Fields] AND “neoplasms”[All 
Fields]) OR “pituitary neoplasms”[All Fields] OR 
(“pituitary”[All Fields] AND “adenoma”[All Fields]) 
OR “pituitary adenoma”[All Fields]) AND survivin [All 
Fields]” as the search strategy and got 26 articles. To find 
out other potentially eligible studies, we also reviewed 
related references, but got no new studies. Meanwhile, 
we tried to contact authors to identify additional studies 
and request missing data (firstly through email, if 
no responses, we would try to contact the authors by 
telephone). Together, we identified 151 articles.
Study selection
Two reviewers selected studies independently. 
Disagreements were settled by discussion or solved by 
a third reviewer. Inclusion criteria were as follows: (1) 
a diagnosis of PA confirmed by a pathologist; (2) PA 
invasiveness as a primary outcome of the study (note: 
generally, invasion/invasiveness is defined as an infiltration 
and often destruction of parasellar tissues, including the 
leptomeninges, subarachnoid space, paranasal sinuses, 
cranial nerves, cavernous venous sinuses, bone and dura. 
The definition of invasiveness and non-invasiveness is 
usually made using radiological evidences of invasion on 
MIR and/or by intra-operative exploration of parasellar 
tissues and sellar walls; (3) a survivin expression model 
established by real-time quantitative polymerase chain 
reaction (qPCR), reverse transcription PCR (RT-PCR), 
immunohistochemistry (IHC) or other reliable molecular-
biological technological means; (4) mean values with SD, 
ORs with 95% CI between survivin expressions and the 
invasiveness could be calculated according to the tables 
or figures in the article (for example, if the study only 
presented primary study data instead of a SD value, we can 
calculate the needy data ourselves), directly obtained, or by 
contacting the authors.
Data extraction
The following data were extracted independently 
by two investigators from the included studies using a 
specially designed table: first author name, publication 
year, nationality, pathology, study methods, invasive 
behaviors, patient numbers, mean age and the positive 
percentage of survivin expressions in the tumor specimen. 
Disagreements between the two investigators would be 
settled by a third reviewer.
Quality assessment
In accordance with the methodological quality 
assessment scale (see Table 2), two investigators 
independently estimated the qualities of the included 
literatures. Disagreement would be solved by discussion. 
In this methodological quality assessment scale, five items, 
including quality control of sample size, source of controls, 
genotyping methods, cases representativeness and HWE 
were checked carefully. The quality scores range between 0 
~ 10, and the higher the score is, the better the qualities are.
Data synthesis and analysis
The meta-analysis was in accord with the PRISMA 
checklists and guidelines (it can be accessed through 
http://www.prisma-statement.org/). All statistical analysis 
was performed using STATA 12.0 (StataCorp LP, College 
Station, TX, USA). Differences were expressed as ORs 
with 95% CIs or SMDs with SD. The I2 tests, Cochran’s 
Q-tests, and Galbraith figures were used to estimate the 
heterogeneities between studies [13, 14]. In the Galbraith 
plot, circles that are all distributed within the region 
bounded by the upper line and lower line indicates that 
there is no statistical heterogeneities. Heterogeneities were 
also considered significant if P < 0.05 (Q statistic) [15]. I2 
values of 75%, 50% and 25% refer to high, moderate and 
low heterogeneities, respectively. The fixed versus random 
effects model should be based on sampling population 
and not purely on heterogeneity considerations. It seems 
likely that there are considerable phenotypic variations 
between populations in the different studies, so we use the 
DerSimonian and Laird random-effects model both studies 
with dichotomous data and studies with continues data 
no matter the I2 was higher than 50% or lower than 50% 
[15]. Theoretically, stratified analysis based on ethnicities 
and methods should be performed to avoid or decrease 
Table 7: The expression of survivin in invasive and non-invasive pituitary adenomas
Type n - + ++ +++ ++++ Positive rate
Invasive 36 19 7 4 3 3 47.22%
Non-invasive 31 20 7 4 0 0 35.48%
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possible bias interference. However, in all the included 
9 studies, only one study was conducted on Caucasian 
population and all the other 8 studies were on Asian 
population, thus the stratified analysis based on ethnicities 
makes little sense. Similarly, for the survivin test methods 
or measurement technique, only 1 study used RT-PCR, 
while all the other 8 studies used HIC, so the thus the 
stratified analysis based on methods was also waived. In 
the future study, when there are more included studies, 
stratified analyses based on ethnicities and methods are 
highly recommended to perform.
Using the one-at-a-time statistical approach (remove 
one individual literature at a time and repeat the analysis 
process), we conducted a sensitivity-analysis to estimate 
the final results’ stability. Funnel plots were drafted 
to assess potential publication-bias. If the plot seems 
symmetric, it’s reasonable to say there is no publication-
bias [16]. The Egger linear regression tests were also 
performed (P < 0.05 suggests publication-bias) [17]. 
Because only 9 studies were included, we did not perform 
the meta-regression analysis.
Further investigation and confirmation
Patients and tissue samples
We included and analyzed 67 surgically resected PA 
samples. Among these patients, there were 30 men and 
37 women. Their ages ranged from 21 to 59 years old. 
Through radiological features on pre-surgical MIR and 
intra-operative impressions, the 67 samples were divided 
into 36 invasive ones and 31 age- and gender-matched 
non-invasive ones. All of these tissues were fixed in 
10% formalin and embedded in paraffin. No patients had 
received preoperative radiotherapy, chemotherapy or any 
other biological therapies.
Immunohistochemistry for survivin
Primary rabbit monoclonal antibodies to human 
survivin and secondary anti-rabbit antibody were used. 
the immnunohistochemical staining procedure was 
conducted based on the Cell Signaling Technology 
protocols. We semiquantitatively calculated the survivin 
immunoreactivities according to the staining-intensity. 
The percentage of positive adenoma cells were blindly 
evaluated in 5 areas at ×400. Standards to evaluate the 
intensity of survivin staining: negative (-), no expression 
or positive cells was 0%; +, light yellow or ≤10%; ++, 
brown yellow or 11%~50%; +++, brown or 51%~75%; 
++++, dark brown or >75%.
Statistical analysis
All computations were carried out using the software 
of SPSS version 13.0 for Windows (SPSS Inc., IL, USA). 
None parameter rank and summing tests were performed. 
Differences were considered statistically significant when 
P was less than 0.05.
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